EU Funded Projects
DiCE is involved in several EU-funded research projects. You can find separate sections dedicated to each of these projects, containing information on their duration, progress, aim, valuable updates about each, DiCE’s role in these, as well as a list of the partners involved, and contact information in case you would like to receive more details on the specific project you are interested in.
There is no effective screening method available in Europe for the prevention of gastric cancer. TOGAS aims to provide the missing evidence-based knowledge that can be used to design, plan and implement appropriate gastric cancer prevention across the EU. Read more.
AI can help clinicians make sense of their own data by automating much of the treatment and analysis. The AIDA project aims to bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Read more.
The GUIDE.MRD project aims to address this challenge by exploring how blood tests could be used to identify which patients might benefit from additional treatment, and which patients would likely not benefit from treatment. The project focuses on patients with lung, pancreatic and colorectal cancers. Read more.
The smartCARE project aims to co-create the Cancer Survivor Smartcard App with third-party app developers. The mobile application provides cancer survivors with easy access to their clinical history and treatment summary, which can be shared with relatives and professionals. Read more.
The aim of the DISCERN project is to identify the causes of three poorly understood cancers in Europe – renal, pancreatic, and colorectal cancer – and to help explain the geographical distribution of these cancer types, including their high incidence in central and eastern Europe. The goal of DISCERN is to uncover novel causes for each of these three cancer types and to provide the critical evidence base required to develop new prevention strategies for these cancers in Europe. Read more.
The overarching objective of SAGITTARIUS is to use liquid biopsy (LB), a new innovative assay for detecting the circulating tumour DNA (ctDNA) in the blood, to personalise the post-surgical care of patients with loco-regional stage III and high-risk stage II colon cancer (LRCC). Read more.